PGP and non-small cell lung carcinoma: While DOX was the administered drug in the cultures with the non small cell lung carcinoma cell line NCI-H460, more generally, all cell lines overexpressing P-gp will show a similar response not only to DOX, but also to other drugs that are P-gp substrates (e.g., paclitaxel).